Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
(2013) In Tumor Biology 34(2). p.637-642- Abstract
- ABSTACT: Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) is an important regulator of cell signaling because of its ability to dephosphorylate receptors of growth factors as well as the cytokines and tyrosine-phosphorylated proteins associated with these receptors. In the current study, we used four different prostate cancer cell lines: PC3, DU145, LNCaP and LNCaP-IL6+. Tumor specimens from 122 patients with prostate cancer were analyzed using a tissue microarray. Our data demonstrate that all four prostate cancer cell lines express the SHP-2 protein. Additionally, low staining intensity and SHP-2 expression in the cytoplasm of cancer cells in prostate tumor specimens was inversely correlated with prostate volume (p = 0.041... (More)
- ABSTACT: Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) is an important regulator of cell signaling because of its ability to dephosphorylate receptors of growth factors as well as the cytokines and tyrosine-phosphorylated proteins associated with these receptors. In the current study, we used four different prostate cancer cell lines: PC3, DU145, LNCaP and LNCaP-IL6+. Tumor specimens from 122 patients with prostate cancer were analyzed using a tissue microarray. Our data demonstrate that all four prostate cancer cell lines express the SHP-2 protein. Additionally, low staining intensity and SHP-2 expression in the cytoplasm of cancer cells in prostate tumor specimens was inversely correlated with prostate volume (p = 0.041 and p = 0.042, respectively) whereas nuclear staining was positively correlated with extracapsular extension (p = 0.039). In our post-prostatectomy specimens, we found that patients with low SHP-2 expression had less favorable outcomes with respect to biochemical recurrence and clinical progression (p = 0.005 and p = 0.018, respectively). The loss of cytoplasmic SHP-2 expression is associated with increased growth and prostatic cancer progression. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3218392
- author
- Tassidis, Helena
LU
; Brokken, Leon
LU
; Jirström, Karin
LU
; Bjartell, Anders LU ; Ulmert, David LU ; Härkönen, Pirkko LU and Gjörloff Wingren, Anette LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Tumor Biology
- volume
- 34
- issue
- 2
- pages
- 637 - 642
- publisher
- Springer
- external identifiers
-
- wos:000316364500004
- pmid:23192641
- scopus:84877110354
- pmid:23192641
- ISSN
- 1423-0380
- DOI
- 10.1007/s13277-012-0590-1
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Urological Cancers (013243420), Pathology, (Lund) (013030000), Tumour Biology, Malmö (013031300) Department affilation moved from v1000588 (Tumour Biology, Malmö) to v1000562 (Department of Translational Medicine) on 2016-01-18 14:39:29.
- id
- eca0c28f-7aa9-44c1-998a-c11ba91448b6 (old id 3218392)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23192641?dopt=Abstract
- date added to LUP
- 2016-04-01 10:12:53
- date last changed
- 2024-01-06 10:47:05
@article{eca0c28f-7aa9-44c1-998a-c11ba91448b6, abstract = {{ABSTACT: Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2) is an important regulator of cell signaling because of its ability to dephosphorylate receptors of growth factors as well as the cytokines and tyrosine-phosphorylated proteins associated with these receptors. In the current study, we used four different prostate cancer cell lines: PC3, DU145, LNCaP and LNCaP-IL6+. Tumor specimens from 122 patients with prostate cancer were analyzed using a tissue microarray. Our data demonstrate that all four prostate cancer cell lines express the SHP-2 protein. Additionally, low staining intensity and SHP-2 expression in the cytoplasm of cancer cells in prostate tumor specimens was inversely correlated with prostate volume (p = 0.041 and p = 0.042, respectively) whereas nuclear staining was positively correlated with extracapsular extension (p = 0.039). In our post-prostatectomy specimens, we found that patients with low SHP-2 expression had less favorable outcomes with respect to biochemical recurrence and clinical progression (p = 0.005 and p = 0.018, respectively). The loss of cytoplasmic SHP-2 expression is associated with increased growth and prostatic cancer progression.}}, author = {{Tassidis, Helena and Brokken, Leon and Jirström, Karin and Bjartell, Anders and Ulmert, David and Härkönen, Pirkko and Gjörloff Wingren, Anette}}, issn = {{1423-0380}}, language = {{eng}}, number = {{2}}, pages = {{637--642}}, publisher = {{Springer}}, series = {{Tumor Biology}}, title = {{Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.}}, url = {{http://dx.doi.org/10.1007/s13277-012-0590-1}}, doi = {{10.1007/s13277-012-0590-1}}, volume = {{34}}, year = {{2013}}, }